[{"Assets_0_FY_USD":525282000.0,"CommonStockSharesOutstanding_0_FY_shares":37906669.0,"NetIncomeLoss_1_FY_USD":-8603000.0,"NetIncomeLoss_4_FY_USD":-47903000.0,"StockholdersEquity_0_FY_USD":307767000.0,"EarningsPerShareBasic_1_FY_USD":-0.23,"EarningsPerShareBasic_4_FY_USD":-1.29,"EarningsPerShareDiluted_1_FY_USD":-0.39,"EarningsPerShareDiluted_4_FY_USD":-1.29,"WeightedAverageNumberOfDilutedSharesOutstanding_4_FY_shares":38288012.0,"WeightedAverageNumberOfSharesOutstandingBasic_4_FY_shares":36997865.0,"Ticker":"TVTX","CIK":"1438533","name":"RETROPHIN, INC.","OfficialName":"Travere Therapeutics Inc. Common Stock","form":"10-K","period":"20161231","fy":"2016.0","fp":"FY","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1905907401.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20170301"}]